Entries |
Document | Title | Date |
20080226547 | Alpha-Emitting Hydroxyapatite Particles - The present invention provides Hydroxyapatite (HA) incorporating an alpha-emitting radionuclide or an in vivo generator for an alpha-emitting radionuclide. The invention further provides methods for the formation of such HA, pharmaceutical compositions comprising the HA and methods of medical treatment of cancerous or noncancerous disease including administering the HA or compositions thereof. | 09-18-2008 |
20080292545 | Functionalized Encoded Apoferritin Nanoparticles and Processes for Making and Using Same - Apoferritin nanoparticles with functionalized surfaces have been prepared that include preselected agents within the cavity of the apoferritin molecule and preselected functionalized surface characteristics on the outer surface of the nanoparticle. Such materials provide for utilization and selective modification in a variety of applications including therapeutic and diagnostic uses. Examples of several of these applications are described herein. In addition a method for the creation of these materials by alternatively assembling, functionalizing, or functionalizing, disassembling and reassemblying the materials provides for creative customization of various types of materials applicable for varying types of applications which are also described herein. | 11-27-2008 |
20090022655 | Nanotubes for Cancer Therapy and Diagnostics - The present invention provides a novel approach to cancer therapy and diagnostics that utilizes nanotubes and other similar nanostructures as both an indirect source of radiation therapy (BNCT), and as delivery vehicles for other types of radio- and chemo-therapeutic materials, as well as imaging agents for diagnostic purposes. | 01-22-2009 |
20090081122 | Injectable superparamagnetic nanoparticles for treatment by hyperthermia and use for forming an hyperthermic implant - The injectable formulation for treatment by hyperthermia comprises a liquid carrier and heat-generating superparamagnetic iron oxide nanoparticles having a mean diameter not greater than 20 nm. Said injectable formulation is able to form in-situ a hyperthermic solid or semi-solid implant upon contact with a body fluid or tissue. Said hyperthermic solid or semi-solid implant may be useful for treating a tumor or a degenerative disc disease by hyperthermia. | 03-26-2009 |
20090092542 | Bioinert tissue marker - This invention relates to a safe, effective, bioinert microporous radiopaque microparticles or spheres as a method and means to mark or provide “localization” of various tissues within the body and to reduce the incidence of adverse tissue reaction. Further, these same microporous particles or spheres comprising the tissue marker(s) are nonmigratory, nonantigenic, and capable of providing selective therapeutic effects, and whereby the macro-colloidal surfaces of both the macroarchitecture and microarchitecture of the spheres or particles scientifically demonstrate the capacity to absorb toxic products of bacterial decay as well as provide neutralizing electron donation activity at the site of the biopsy or therapeutic intervention as well as proximate to the site of placement; both at the macro-scale of each sphere as well as within the microarchitecture of each particle or sphere, and a bioinert tissue marker whereby the pores on the surface of each sphere are connected to the pores each sphere by blow-holes, and the internal pores are in turn interconnected thus capable of hosting gases, liquids, organic substances, inorganic substances, nanostructures, nanoparticles and nanomaterials. | 04-09-2009 |
20090098044 | SOLID PARTICLES FROM CONTROLLED DESTABILISATION OF MICROEMULSIONS - The present invention relates to a process for making a particulate substance. The process comprises providing an emulsion, optionally a microemulsion, comprising droplets dispersed in a continuous liquid phase. At least some of the droplets of the emulsion comprise nuclei. The droplets are then at least partially destabilised to form the particulate substance. | 04-16-2009 |
20090110633 | Nanocells for Diagnosis and Treatment of Diseases and Disorders - The present invention relates to novel nanocell compositions and their use in imaging, diagnostic and treatment methods. In one embodiment, nanocells tailored for imaging methods comprise a nanocore surrounded by a lipid matrix, and are modified to contain a radionuclide core or a nanocore with an emission spectra. The nanocells may be size restricted such as being greater than about 60 nm so that they selectively extravasate at sites of angiogenesis (e.g. tumor) and do not pass through normal vasculature or enter non-tumor bearing tissue. In this way, angiogenic sites can be both detected and treated. In another embodiment, nanocells are tailored for various treatment methods, including the treatment of brain cancer, asthma, Grave's Disease, Cystic Fibrosis, and Pulmonary Fibrosis. | 04-30-2009 |
20090110634 | RADIOLABELLED NANOPARTICLES - The present invention relates to radiolabelled nanoparticles having a radioisotope non-covalently bonded thereto. The radiolabelled nanoparticles are useful as radiopharmaceuticals. Kits and methods of preparation of the radiolabelled nanoparticles are also disclosed. | 04-30-2009 |
20090162277 | Lysophospholipids Solubilized Single-Walled Carbon Nanotubes - Lipophilic compounds extracted from cell growth mediums, particularly lysophospholipids are used to solubilize single-walled nanotubes. The naturally occurring lysophospholipids were found to readily bond to the exterior wall of the single-walled nanotubes to enhance the biocompatibility of the single-walled nanotubes in therapeutic and diagnostic conditions. The solubilization protocol is simple, highly efficient, and results in a population of coated single-walled nanotubes which are highly stable. | 06-25-2009 |
20090169471 | PARTICLES FOR INJECTION AND PROCESSES FOR FORMING THE SAME - According to an aspect of the invention, injectable particles are provided that include (a) porous polymeric particles that contain at least one type of particle-forming polymer and (b) a pore-filling composition that includes at least one therapeutic agent and at least one pore-filling polymer. The pore-filling composition at least partially fills the pores of the injectable porous polymeric particles. Other aspects of the invention pertain to methods of making such particles. | 07-02-2009 |
20090175785 | Self-Assembled Fmoc-Ff Hydrogels - Novel peptide-based hydrogels, composed of short aromatic peptides (e.g., homodipeptides of aromatic amino acid residues) are disclosed. The hydrogels are characterized by remarkable rigidity and biocompatibility. Further disclosed are uses of these hydrogels in applications such as tissue engineering, drug delivery, cosmetics, implantation, packaging and the like. Further disclosed are processes and kits for preparing these hydrogels. | 07-09-2009 |
20090246126 | Thulium-based capsule and devices for use in high dose rate brachytherapy - A capsule for high dose rate brachytherapy, wherein the capsule comprises within its interior space thulium-170, and further comprises at least one layer of a radiation emission modifying metal (e.g., gold), wherein said layer is provided either internally within the capsule or on the outer surface thereof. | 10-01-2009 |
20090297437 | RADIOACTIVE DEVICE - A radioactive or radioactivable nanostructure has a core, the core including at least two atoms, at least one of which being radioactive or radioactivable, and a shell encapsulating the core and selected among a selected material so that at the most, 20% of the radioactive radiation produced by the core are stopped or absorbed by the shell and the manufacturing method thereof. | 12-03-2009 |
20100034735 | TARGETED NANOPARTICLES FOR CANCER DIAGNOSIS AND TREATMENT - The invention provides modified gold nanoparticles that enable a non-invasive, real time, targeted cancer imaging-therapeutic in one step. After reaching the cancer targets, the designed targeted gold nanoparticles significantly enhance conventional treatment modalities at the cellular level. In this aspect the gold nanoparticles of the invention are modified to be bound to a Positron Emission Tomography (PET) tracer. | 02-11-2010 |
20100047163 | Synthetic LDL as Targeted Drug Delivery Vehicle - The present invention provides a synthetic LDL nanoparticle comprising a lipid moiety and a synthetic chimeric peptide so s to be capable of binding the LDL receptor. The synthetic LDL nanoparticle of the present invention is capable of c incorporating and targeting therapeutics for diseases associated with the expression of the LDL receptor. The invention further provides methods of using such synthetic LDL nanoparticles. | 02-25-2010 |
20100092384 | MULTIFUNCTIONAL NANOPARTICLES AND COMPOSITIONS AND METHODS OF USE THEREOF - Provided is a multifunctional particle comprising: (a) an inner metallic core, (b) a biocompatible shell comprising an optical contrast agent embedded therein, and (c) a targeting biomolecule conjugated to the biocompatible shell through a multidentate ligand, wherein the multidentate ligand is chelated to an imaging agent. Also provided are compositions comprising the multifunctional particle and methods of using the multifunctional particle, including a method of diagnostic imaging and a method of treatment. | 04-15-2010 |
20100111841 | Compositions and methods for surface abrasion with frozen particles - Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue. | 05-06-2010 |
20100111842 | Compositions and methods for therapeutic delivery with frozen particles - Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue. | 05-06-2010 |
20100111843 | Compositions and methods for therapeutic delivery with frozen particles - Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue. | 05-06-2010 |
20100111844 | Compositions and methods for therapeutic delivery with frozen particles - Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue. | 05-06-2010 |
20100111845 | Compositions and methods for therapeutic delivery with frozen particles - Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue. | 05-06-2010 |
20100111846 | Compositions and methods for delivery of frozen particle adhesives - Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue. | 05-06-2010 |
20100111847 | Compositions and methods for administering compartmentalized frozen particles - Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue. | 05-06-2010 |
20100111848 | Compositions and methods for administering compartmentalized frozen particles - Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue. | 05-06-2010 |
20100111849 | Compositions and methods for administering compartmentalized frozen particles - Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue. | 05-06-2010 |
20100111850 | Compositions and methods for administering compartmentalized frozen particles - Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue. | 05-06-2010 |
20100143243 | Frozen compositions and methods for piercing a substrate - Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue. | 06-10-2010 |
20100150828 | RADIOACTIVE GOLD NANOPARTICLES AND METHODS OF MAKING AND USING THEM - Methods of preparing a composition comprising non-ionic, radioactive gold nanoparticles (R-GNPs) are disclosed. The method comprises: a) providing a solution comprising gold (Au-197) ions; and b) exposing the solution to neutron irradiation to generate a composition comprising non-ionic R-GNPs. Alternatively, the method comprises: a) providing a solution that comprises a composition comprising gold (Au-197) nanoparticles (GNPs); and b) exposing the GNP solution to neutron irradiation to generate a composition comprising non-ionic R-GNPs. Compositions that comprises non-ionic R-GNPs encapsulated within and/or anchored to MSNs, and methods of making the same are also disclosed. | 06-17-2010 |
20100158800 | DRUG DEPOT IMPLANT DESIGNS AND METHODS OF IMPLANTATION - The present invention relates to novel drug depot implant designs for optimal delivery of therapeutic agents to subjects. The invention provides a method for alleviating pain associated with neuromuscular or skeletal injury or inflammation by targeted delivery of one or more therapeutic agents to inhibit the inflammatory response which ultimately causes acute or chronic pain. Controlled and directed delivery can be provided by drug depot implants, comprising therapeutic agents, specifically designed to deliver the therapeutic agent to the desired location by facilitating their implantation, minimizing their migration from the desired tissue location, and without disrupting normal joint and soft tissue movement. | 06-24-2010 |
20100172831 | Protein-Modified Nano-Droplets, Compositions and Methods of Production - A protein-modified droplet includes a droplet having a liquid material, and a protein structure formed to at least partially enclose the droplet. The protein structure includes a plurality of protein molecules having an affinity to at least a region of the droplet during formation of the protein structure, and the droplet has a maximum dimension of at least about 1 nm and less than about 1000 nm. A composition includes a plurality of protein-modified droplets dispersed in an aqueous solution. | 07-08-2010 |
20100178244 | Biocompatible Microbubbles to Deliver Radioactive Compounds to Tumors, Atherosclerotic Plaques, Joints and Other Targeted Sites - A composition and method for targeted use of radionuclide therapy for the treatment of cancer and cancerous tumors, atherosclerotic plaques, joints and other targeted sites. Microparticles, microbubbles, or nanoparticles deliver therapeutic doses of radiation, included radiation from alpha emitting radionuclides, to sites in a patient. The delivery may be targeted by targeting agents linked to the microparticles, microbubbles, or nanoparticles or by the external application of energy, or both. | 07-15-2010 |
20100178245 | Biocompatible Microbubbles to Deliver Radioactive Compounds to Tumors, Atherosclerotic Plaques, Joints and Other Targeted Sites - A composition and method for targeted use of radionuclide therapy for the treatment of cancer and cancerous tumors, atherosclerotic plaques, joints and other targeted sites. Microparticles, microbubbles, or nanoparticles deliver therapeutic doses of radiation, included radiation from alpha emitting radionuclides, to sites in a patient. The delivery may be targeted by targeting agents linked to the microparticles, microbubbles, or nanoparticles or by the external application of energy, or both. | 07-15-2010 |
20100183504 | MULTIMODAL IMAGING PROBES FOR IN VIVO TARGETED AND NON-TARGETED IMAGING AND THERAPEUTICS - In certain embodiments this invention provides a nanoparticle-based technology platform for multimodal in vivo imaging and therapy. The nanoparticle-based probes detects diseased cells by MRI, PET or deep tissue Near Infrared (NIR) imaging, and are capable of detecting diseased cells with greater sensitivity than is possible with existing technologies. The probes also target molecules that localize to normal or diseased cells, and initiates apoptosis of diseased cells. | 07-22-2010 |
20100254897 | Seeds and Markers for Use in Imaging - A contrast marker having a casing and a novel MRI contrast agent comprising metal complexes disposed around, within, or abuting the casing is provided. Such contrast markers may be placed in a strand, with or without a therapy seed, to produce a seeded strand useful for imaging and in connection with brachytherapy. | 10-07-2010 |
20100266491 | SYSTEM FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS - The present invention provides a drug delivery system for targeted delivery of therapeutic agent-containing particles to tissues, cells, and intracellular compartments. The invention provides targeted particles comprising a particle, one or more targeting moieties, and one or more therapeutic agents to be delivered and pharmaceutical compositions comprising inventive targeted particles. The present invention provides methods of designing, manufacturing, and using inventive targeted particles and pharmaceutical compositions thereof. | 10-21-2010 |
20100290983 | Compositions and Methods for Drug Delivery - The present disclosure is directed to surface-modified particles and to methods of making and using the same. The surface-modified particles comprise a particle core and a coating associated with the particle core, wherein the particle core comprises an active agent, the coating comprises a surfactant having formula I, and the surface-modified particle has an average size from about 1 nm to about 2,000 nm: | 11-18-2010 |
20110027172 | DRUG DELIVERY SYSTEM FOR PHARMACEUTICALS AND RADIATION - The present invention provides a drug delivery system for delivery of an agent and a radiopharmaceutical agent. The drug delivery system may specifically target an organ, tissue, cells, extracellular matrix, or intracellular compartment. Typically, the drug delivery system is a particle. Pharmaceutical compositions comprising the inventive particles are also provided. The present invention provides methods of preparing and using the inventive particles and pharmaceutical compositions. The inventive particles are useful in treating and diagnosing a variety of diseases including cancer. The inventive particles are also useful in tracking particles in vivo. | 02-03-2011 |
20110129413 | Bioconjugation of Calcium Phosphosilicate Nanoparticles For Selective Targeting of Cells In Vivo - Non-aggregating resorbable calcium phosphosilicate nanoparticles (CPNPs) are bioconjugated to targeting molecules that are specific for particular cells. The CPNPs are stable particles at normal physiological pH. Chemotherapy and imaging agents may be integrally formed with the CPNPs so that they are compartmentalized within the CPNPs. In this manner, the agents are protected from interaction with the environment at normal physiological pH. However, once the CPNPs have been taken up, at intracellular pH, the CPNPs dissolve releasing the agent. Thus, chemotherapeutic or imaging agents are delivered to specific cells and permit the treatment and/or imaging of those cells. Use of the bioconjugated CPNPs both limits the amount of systemic exposure to the agent and delivers a higher concentration of the agent to the cell. The methods and principals of bioconjugating CPNPs are taught by examples of bioconjugation of targeting molecules for breast cancer, pancreatic cancer, and leukemia. | 06-02-2011 |
20110200526 | System for Concurrent Delivery of Thermobrachytherapy in the Treatment of Cancers - A system combines hyperthermia and radiation treatments in a single treatment modality by using a radioactive seed having magnetic properties. | 08-18-2011 |
20110286915 | Nanocarriers for Drug Delivery - The present invention provides a nanocarrier having an interior and an exterior, the nanocarrier comprising at least one conjugate, wherein each conjugate includes a polyethylene glycol (PEG) polymer. Each conjugate also includes at least two amphiphilic compounds having both a hydrophilic face and a hydrophobic face. In addition, each conjugate includes an oligomer, wherein at least 2 of the amphiphilic compounds are covalently attached to the oligomer which is covalently attached to the PEG. The nanocarrier is such that each conjugate self-assembles in an aqueous solvent to form the nanocarrier such that a hydrophobic pocket is formed in the interior of the nanocarrier by the orientation of the hydrophobic face of each amphiphilic compound towards each other, and wherein the PEG of each conjugate self-assembles on the exterior of the nanocarrier. | 11-24-2011 |
20120020879 | PROCESS, COMPOSITION AND METHOD FOR ANION DEPOSITION INTO FERRITIN FOR THERAPEUTIC AND OTHER USE - Provided herein is a process for production of a metal nanoparticle, the process comprising providing a first solution containing a protein nanocage complex comprising a hydrophobic metal core and an ion-transport mechanism, providing a second solution containing a preselected anionic agent, combining the first and second solutions into a third combined solution, and applying an external method to the third combined solution to manipulate the metal core's redox state, in which reduction of the metal core causes the preselected anionic agent to be imported and incorporated into the metal core. Also provided herein is a composition from the process and a method of use. | 01-26-2012 |
20120058048 | DIRECTED RADIOTHERAPY - The present invention relates enhanced targeting of drug delivery vehicles to vascular endothelial cells | 03-08-2012 |
20120070371 | Low-Density Magnesium-Aluminum-Silicate (MAS) Microparticles for Radiotherapy and/or Radioimaging - This invention relates to low density radioactive magnesium-aluminum-silicate (MAS) microparticles that contain either samarium-yttrium, samarium, or lutetium as medical isotopes for radiotherapy and/or radioimaging. | 03-22-2012 |
20120076723 | DEVICES AND METHODS FOR THE TREATMENT OF CANCER - The invention relates to the treatment of cancer. In particular the invention relates to an internal therapeutic product comprising: (i) an anti-cancer component selected from one or both of: a radionucleotide, a cytotoxic drug; and (ii) a silicon component selected from one or more of: resorbable silicon, biocompatible silicon, bioactive silicon, porous silicon, polycrystalline silicon, amorphous silicon, and bulk crystalline silicon, the internal therapeutic product being for the treatment of cancer. | 03-29-2012 |
20120093718 | LIPOSOMAL NANOPARTICLES AND OTHER FORMULATIONS OF FENRETINIDE FOR USE IN THERAPY AND DRUG DELIVERY - Formulations of neutral retinoids, in particular fenretinide (HPR) in the form of lipid nanoparticles, solid dipersions and emulsions are disclosed. These compositions are used to treat diseases that are amenable to treatment by HPR, such as neoplastic diseases by achieving higher and more prolonged concentrations of HPR in the subject. The key steps for preparing lipid nanovesicles of HPR include mixing and sonication, sterile filtration, without or without lyophilization for long-term stable storage, and employ processes and materials that are scalable from the laboratory to the manufacturing level. The formulation are suitable for injection into human or animal patients without causing allergic or hypersensitivity responses by avoiding chemical surfactants and animal sources of phospholipids in their manufacture. | 04-19-2012 |
20120134918 | GUM ARABIC COATED 198GOLD RADIOACTIVE NANOPARTICLES FOR CANCER THERAPY - The invention provides a cancer therapeutic and imaging agent comprising a solution containing Gum Arabic coated | 05-31-2012 |
20120134919 | Ion substituted calcium phosphate particles - A method for formation of spherical particles of ion substituted calcium phosphate. The method is based on precipitation of particles from a buffered solution under static, stirring or hydrothermal conditions. Also, the use of the formed materials and the particles in itself. | 05-31-2012 |
20120269722 | CHEMOEMBOLISATION - A composition for chemoembolotherapy of solid tumours comprises particles of a water-insoluble water-swellable synthetic anionic polymer and, absorbed therein an anthracycline. Suitably the polymer is a poly(vinyl alcohol) based polymer and the drug is doxorubicin. | 10-25-2012 |
20130004417 | Gold Coated Lanthanide Nanoparticles - The present invention is directed α-particle emitting nanoparticles that comprise a lanthanide phosphate sequestration shell enclosing an α-emitting-radioisotope-doped lanthanide phosphate core such that the shell allows at least some of the α emissions from the α-emitting radioisotope to pass therethrough and prevents at least some radioactive decay products of the α-emitting radioisotope from exiting the α-particle emitting nanoparticle. Further, such α-particle emitting nanoparticles may be coated with gold and functionalized. Additionally, a method for making and using the same are disclosed. | 01-03-2013 |
20130011333 | Methods and Compositions for Nanoparticle-Mediated Cancer Cell-Targeted Delivery - The present invention provides methods and compositions to selectively and directly deliver nanoparticles carrying an active agent to tumor cells. The active agent is internalized by the tumor cells, producing an anti-tumor effect for therapeutic applications and/or depositing a detectable marker for diagnostic applications. The present invention further provides a p53 chimera that circumvents the dominant negative activity of mutant p53 as a therapeutic in the treatment of cancer and reduction of mor size. | 01-10-2013 |
20130045161 | METHODS AND COMPOSITIONS FOR TARGETED IMAGING - A new approach to targeting imaging agents to macrophage-rich sites of interest is disclosed. Compositions of the invention are rHDL and HDL-like liposomal compositions, protein constituents of which, apolipoproteins A-I and/or A-II or fragments thereof are used not only as structural but also as targeting agents. This is achieved by certain controlled chemical or enzymatic modification of apolipoproteins A-I or A-II or fragments thereof. Such modification converts these apolipoproteins to substrates for macrophage scavenger receptors and results in the improvement of contrast agent-(HDL/modified apolipoprotein)-particle association with macrophages and/or absorption (uptake) by macrophages when compared to that of the contrast agent-(HDL/apolipoprotein)-particle constructed with non-modified naturally occurring apo A-I. The compositions can be used for noninvasive specific in vivo molecular detection and localization of macrophage-rich sites of interest using imaging techniques such as computed tomography (CT), gamma-scintigraphy, positron emission tomography (PET), single photon emission computed tomography (SPECT), magnetic resonance imaging (MRI). | 02-21-2013 |
20130045162 | DELIVERY SYSTEM FOR SPECIFICALLY TARGETING CANCER CELLS AND METHOD OF USE THEREOF - Methods for prevention, treatment or inhibition of the growth or metastasis of cancer cells in a subject are disclosed. One method comprises the step of administering to the subject a therapeutically effective amount of tumor associated antigen binding ligand-coated planetary ball milled (PBM) nanoparticles containing a cytotoxic agent. | 02-21-2013 |
20130052127 | COMPOSITE BODY FOR ANTIGEN OR DRUG DELIVERY - The invention provides an antigen or drug delivery complex containing a complex of an antigen or drug and a cationic molecule, and an anionic molecule encapsulating the same. The antigen or drug delivery complex can be used as a main component of a drug delivery system that delivers various antigens and drugs to a particular cell or organ. | 02-28-2013 |
20130071322 | MEDICAL TREATMENT APPLICATIONS OF SWELLABLE AND DEFORMABLE MICROSPHERES - A method for medical treatment was developed in which microspheres with novel properties are administered in a mammal. The microspheres are made using a novel process that results in microspheres with new combined properties of high density, low fracture, high swell capacity, rapid swell, and deformability following swell. These microspheres may be administered for void filling, tissue bulking, non-vasculature occlusion, body fluid absorption, and delivery of medications. | 03-21-2013 |
20130095032 | LIPIDATED GLYCOSAMINOGLYCAN PARTICLES AND THEIR USE IN DRUG AND GENE DELIVERY FOR DIAGNOSIS AND THERAPY - Lipidated glycosaminoglycan particles, prepared by reacting a glycosaminoglycan with at least one lipid to cross-link the carboxylic acid groups in the glycosaminoglycan with a primary amine in the lipid, are used to encapsulate drugs for use in the treatment of pathological conditions in an animal. | 04-18-2013 |
20130129618 | EGCG STABILIZED GOLD NANOPARTICLES AND METHOD FOR MAKING SAME - The invention provides stabilized, biocompatible gold nanoparticles that are stabilized with material from epigallocatechin Gallate (EGCg), which is a polyphenols- or flavanoids-rich plant material that can be obtained from green tea. The EGCg is an an antioxidant reducing agent derived from green tea. The gold nanoparticles of the invention can be radioactive or non radioactive and are formed via a simple room temperature fabrication method. In preferred embodiment method of making, an aqueous solution containing gold salts is provided. The aqueous solution is mixed with EGCg in a buffer, such as deionized water. The gold salts react to form biocompatible gold nanoparticles that are stabilized with a coating of EGCg. The thermodynamically feasible redox couple of AuCl4-EGCg leading to the reduction of AuCl4- by EGCg to form gold nanoparticles. In another embodiment, pre-cooled gold salt and EGCg solutions form multi-layered EGCg coated particles. | 05-23-2013 |
20130195755 | MICELLULAR COMBINATION COMPRISING A NANOPARTICLE AND A PLURALITY OF SURFMER LIGANDS - The field of the present invention relates to the stabilisation of nanoparticles in aqueous dispersion and, in particular, the stabilisation of nanoparticles by encapsulating the nanoparticles in a micellular combination. The field of the present invention further relates to a micellular combination of nanoparticles and a method of manufacture of the micellular combination and uses thereof. In a first aspect the present disclosure teaches a micellular combination that allows the stable dispersion of nanoparticles into aqueous environment. The micellular combination comprises at least one nanoparticle in a core of the micellular combination. A plurality of surfactants is co-assembled with a plurality of hydrophobic ligands on the surface of the nanoparticle in such a way that the hydrophilic part of the surfactant forms a hydrophilic shell around the core of the micellular combination. | 08-01-2013 |
20130216474 | NANOCELLS FOR DIAGNOSIS AND TREATMENT OF DISEASES AND DISORDERS - The present invention relates to novel nanocell compositions and their use in imaging, diagnostic and treatment methods. In one embodiment, nanocells tailored for imaging methods comprise a nanocore surrounded by a lipid matrix, and are modified to contain a radionuclide core or a nanocore with an emission spectra. The nanocells may be size restricted such as being greater than about 60 nm so that they selectively extravasate at sites of angiogenesis (e.g. tumor) and do not pass through normal vasculature or enter non-tumor bearing tissue. In this way, angiogenic sites can be both detected and treated. In another embodiment, nanocells are tailored for various treatment methods, including the treatment of brain cancer, asthma, Grave's Disease, Cystic Fibrosis, and Pulmonary Fibrosis. | 08-22-2013 |
20130243689 | MULTI-COMPARTMENTAL MACROPHAGE DELIVERY - Disclosed are multi-compartmental nanoparticulate systems for imaging as well as the diagnosis, monitoring, and treatment of inflammation and/or disease. These multicompartmental nanoparticulate systems can be used to target specific cells or ceullular structures. Furthermore, these systems are capable of simultaneous delivery of hydrophilic and lipophilic compositions. Finally, these systems also allow for temporal control of drug delivery. | 09-19-2013 |
20130266509 | METHOD FOR COATING AND FUNCTIONALIZING NANOPARTICLES BY MEANS OF A MICHAEL REACTION - The present invention relates to a method for coating nanoparticles to achieve stable dispersions of said particles in a liquid medium and the surface functionalization thereof with groups that have physical activity such as luminescence, chemical activity such as catalytic capacity and/or biological activity such as a capacity for selectively binding with a biological entity. | 10-10-2013 |
20130309167 | Seeds and Markers for Use in Imaging - A contrast marker having a casing and a novel MRI contrast agent comprising metal complexes disposed around, within, or abuting the casing is provided. Such contrast markers may be placed in a strand, with or without a therapy seed, to produce a seeded strand useful for imaging and in connection with brachytherapy. | 11-21-2013 |
20130336884 | NANOPARTICLE FABRICATION METHODS, SYSTEMS, AND MATERIALS FOR FABRICATING ARTIFICIAL RED BLOOD CELLS - A plurality of artificial red blood cell particles includes each particle of the plurality being substantially monodisperse and each particle having a largest common linear dimension of about 5 μm to about 10 μm. The particles can also have a modulus configured such that a particle of the plurality of particles can pass through a tube having an inner diameter of less than about 3 μm. | 12-19-2013 |
20140099255 | POLYMER BASED RADIONUCLIDE CONTAINING PARTICULATE MATERIAL - The invention relates to a particulate material having a diameter in the range of from 5 to 200 microns comprising polymeric matrix and stably incorporated radionuclide, processes for its production and a method of radiation therapy utilising the particulate material. | 04-10-2014 |
20140099256 | RADIOACTIVE LUMINESCENT NANOPARTICLE COMPOSITIONS - An embodiment of the invention is directed to a composition comprising a luminescent noble metal nanoparticle, wherein the surface of the noble metal nanoparticle is coated with a ligand, and wherein the noble metal nanoparticle is about 2 nm to 5 nm in diameter and further wherein a portion of the noble metal is present as its radioactive isotope. In an embodiment of the invention, the radioactive isotope is present at a concentration of up to 2% w/w of the noble metal. | 04-10-2014 |
20140178297 | Seeds and Markers for Use in Imaging - A contrast marker having a casing and a novel MRI contrast agent comprising metal complexes disposed around, within, or abuting the casing is provided. Such contrast markers may be placed in a strand, with or without a therapy seed, to produce a seeded strand useful for imaging and in connection with brachytherapy. | 06-26-2014 |
20140193331 | MULTIFUNCTIONAL INFRARED-EMITTING COMPOSITES - Disclosed is a method of non-invasive infrared imaging, comprising (a) administering a composition containing infrared-emitting particles which contain rare earth elements that emit in the short-wavelength infrared (SWIR) spectrum, where the particles are encapsulated with a biocompatible matrix to form downconverting encapsulated particles; and (b) irradiating with infrared radiation, where both excitation and emission spectra of the encapsulated particles are in the infrared region. Analogous methods of image-guided biomedical intervention, and drug tracking and delivery are also disclosed. Also disclosed is a composition for biomedical applications, containing infrared-emitting particles which contain rare earth-elements that emit in the short-wavelength infrared (SWIR) spectrum, where the particles are encapsulated with a biocompatible matrix to form downconverting encapsulated particles. | 07-10-2014 |
20140212355 | TRANS-ARTERIAL DRUG DELIVERY - It is provided herein methods, devices, and compositions for trans-arterial local delivery of therapeutic agent for the treatment of liver cancers. | 07-31-2014 |
20140248210 | MULTIMODAL SILICA-BASED NANOPARTICLES - The present invention provides a fluorescent silica-based nanoparticle that allows for precise detection, characterization, monitoring and treatment of a disease such as cancer. The nanoparticle has a range of diameters including between about 0.1 nm and about 100 nm, between about 0.5 nm and about 50 nm, between about 1 nm and about 25 nm, between about 1 nm and about 15 nm, or between about 1 nm and about 8 nm. The nanoparticle has a fluorescent compound positioned within the nanoparticle, and has greater brightness and fluorescent quantum yield than the free fluorescent compound. The nanoparticle also exhibits high biostability and biocompatibility. To facilitate efficient urinary excretion of the nanoparticle, it may be coated with an organic polymer, such as poly(ethylene glycol) (PEG). The small size of the nanoparticle, the silica base and the organic polymer coating minimizes the toxicity of the nanoparticle when administered in vivo. In order to target a specific cell type, the nanoparticle may further be conjugated to a ligand, which is capable of binding to a cellular component associated with the specific cell type, such as a tumor marker. In one embodiment, a therapeutic agent may be attached to the nanoparticle. To permit the nanoparticle to be detectable by not only optical fluorescence imaging, but also other imaging techniques, such as positron emission tomography (PET), single photon emission computed tomography (SPECT), computerized tomography (CT), bioluminescence imaging, and magnetic resonance imaging (MRI), radionuclides/radiometals or paramagnetic ions may be conjugated to the nanoparticle. | 09-04-2014 |
20140335015 | NANOPARTICLES COMPRISING METALLIC AND HAFNIUM OXIDE MATERIALS, PREPARATION AND USES THEREOF - The present invention relates to novel nanoparticles which can be advantageously used in the health sector as diagnostic and/or therapeutic agents. Nanoparticles of the invention comprise a metallic material at least partly covered with an hafnium oxide material or embedded therein. When compared to existing products, these nanoparticles offer a remarkable benefit over risk ratio. Specifically, these nanoparticles potentiate the efficiency of known metallic nanoparticles. Indeed, they retain the metal intrinsic properties and are now in addition safely usable in a mammal, in particular in a human being. The invention also relates to methods for producing said nanoparticles, to compositions containing same, and to uses thereof. | 11-13-2014 |
20140377170 | VIRION-DERIVED NANOSPHERES FOR SELECTIVE DELIVERY OF THERAPEUTIC AND DIAGNOSTIC AGENTS TO CANCER CELLS - The invention relates to methods for producing papilloma-derived nanosphere particles that contain therapeutic, diagnostic, or other agents. The invention also provides nanosphere particle preparations that are useful for selectively delivering therapeutic, diagnostic, and/or other agents to cancer cells of subjects without eliciting a serotype-specific immunogenic response in the subjects. | 12-25-2014 |
20150037250 | CONTRAST AGENT - According to one embodiment, a contrast agent includes a blood vessel contrast enhancement particles configured to enhance contrast of a blood vessel of an object and a diseased tissue contrast enhancement particles configured to enhance contrast of a diseased tissue of the object. The blood vessel contrast enhancement particles have a first particle size larger than a gap of vascular endothelial cells under an EPR effect. The diseased tissue contrast enhancement particles have a second particle size smaller than the gap. | 02-05-2015 |
20150064107 | IMAGING AGENT - The invention relates to imaging agents, and in particular to multi-modal nanoparticle (NPIA) imaging agents offering magnetic, radionuclide and fluorescent imaging capabilities to exploit the complementary advantages of magnetic resonance imaging (MRI), positron emission tomography (PET), single-photon emission computed tomography (SPECT) and optical imaging (OI). The invention extends to these new types of agents per se, and to uses of such agents in various biomedical applications, such as in therapy and in diagnosis. | 03-05-2015 |
20150098899 | Particulate Materials And Compositions For Radio Therapy - Timed-bioresorbable particulates, particularly microspheres or fibers, may be used as a vehicle for delivery of radioisotopes, such as Y-90 and Pd-103 for localized radiotherapy, or as an embolic device. These particulates may also be embedded in polymers, or dispersed in injectable gels or other injectable media for the treatment of various cancers. The benefit of bioresorption, the ability to control the ratio of radioisotopes in the particulate, especially the gamma and beta ratios such as In-111/Y-90 ratio in a particulate, and the benefit of non-conductive implants are disclosed. | 04-09-2015 |
20150343091 | NANOPARTICLE DRUG CONJUGATES - Described herein are nanoparticle drug conjugates (NDCs), which, in certain embodiments, comprise a non-toxic, multi-modality, clinically proven silica-based nanoparticle platform with covalently attached drug molecules/moieties. The nanoparticle drug conjugates (NDCs) demonstrate imaging capability and targeting ligands which efficiently clear through the kidneys. Furthermore, the conjugates incorporate therapeutic agents for cancer detection, prevention, and/or treatment. | 12-03-2015 |
20160113882 | LIPIDATED GLYCOSAMINOGLYCAN PARTICLES AND THEIR USE IN DRUG AND GENE DELIVERY FOR DIAGNOSIS AND THERAPY - Lipidated glycosaminoglycan particles, prepared by reacting a glycosaminoglycan with at least one lipid to cross-link the carboxylic acid groups in the glycosaminoglycan with a primary amine in the lipid, are used to encapsulate drugs for use in the treatment of pathological conditions in an animal. | 04-28-2016 |
20160184466 | TRACEABLE DEVICES FOR GASTROINTESTINAL USE AND METHODS OF USE AND MANUFACTURING THE SAME - A traceable device and procedure suitable for investigating gastrointestinal motility disorders by measuring transit time of the device as it is passed through the gastrointestinal tract of a patient. The device includes a core material configured to be imaged with a gamma imaging process and optionally also an x-ray imaging process, and a sealing material substantially insoluble in gastrointestinal fluids and fully encapsulating the core material. | 06-30-2016 |